EU Revises Annex VI of CLP Regulation, New Rules to Take Effect in 2027

On June 20, 2025, the EU Official Journal published Commission Delegated Regulation (EU) 2025/1222, amending Section III, Table 3 of Annex VI to the Classification, Labelling and Packaging Regulation (CLP Regulation) (EC) No 1272/2008. The revision updates harmonized classification and labeling standards for several substances to align with the latest scientific risk assessments.

Implementation Timeline

Effective Date: The regulation enters into force 20 days after publication in the EU Official Journal.
Mandatory Compliance: From February 1, 2027, all chemicals and mixtures placed on the EU market must comply with the updated requirements.
Voluntary Transition Period: Companies can adopt the new standards in advance of the effective date to ease the compliance burden.

CIRS Insights

EU chemical manufacturers, importers, and downstream users should closely review the specific substance lists (see Annex VI of the Regulation) and adjust production processes, labeling designs, and supply chain management. Businesses are advised to utilize the transition period to achieve compliance and avoid market access restrictions due to non-compliance.

Key Amendments

Part 3, Table 3, of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

(1) the following entries are inserted following the consecutive order of the index numbers corresponding to each entry:

Index No	Chemical Name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATEs	Notes
Index No	Chemical Name	EC No	CAS No	Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)	Specific Conc. Limits, M-factors and ATEs	Notes
‘607-776-00-5	2-ethylhexanoic acid, monoester with propane-1,2-diol	285-503-5	85114-00-7	Repr. 1B	H360D	GHS08 Dgr	H360D’
‘612-300-00-4	N-1-naphthylaniline; N-phenylnaphthalen-1-amine	201-983-0	90-30-2	Acute Tox. 4 STOT RE 2 Skin Sens. 1	H302 H373 (blood system, liver) H317	GHS07 GHS08 Wng	H302 H373 (blood system, liver) H317		oral: ATE = 1 200 mg/kg bw’
‘026-005-00-8	tetrairon tris(pyrophosphate); ferric pyrophosphate	233-190-0	10058-44-3	Eye Irrit. 2	H319	GHS07 Wng	H319’
‘604-103-00-7	α,α’-propylenedinitrilodi-o-cresol	202-374-2	94-91-7	Repr. 1B	H360FD	GHS08 Dgr	H360FD’
‘008-004-00-4	ozone	233-069-2	10028-15-6	Ox. Gas 1 Carc. 2 Muta. 2 Acute Tox. 1 STOT SE 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H270 H351 H341 H330 H370 (nervous system, respiratory system, cardiovascular system) H372 (nervous system, respiratory system) H400 H410	GHS03 GHS08 GHS06 GHS09 Dgr	H270 H351 H341 H330 H370 (nervous system, respiratory system, cardiovascular system) H372 (nervous system, respiratory system) H410		inhalation: ATE = 10 ppmV STOT SE 1; H370: C ≥ 0,002 % STOT SE 2; H371: 0,0005 % ≤ C < 0,002 % STOT RE 1; H372: C ≥ 0,05 % STOT RE 2; H373: 0,01 % ≤ C < 0,05 % M = 100 M = 1’
‘007-031-00-9	dinitrogen oxide	233-032-0	10024-97-2	Repr. 1B STOT SE 3 STOT RE 1 Ozone 1	H360Df H336 H372 (nervous system) H420	GHS08 GHS07 Dgr	H360Df H336 H372 (nervous system) H420’
‘056-006-00-9	barium chromate	233-660-5	10294-40-3	Carc. 1B	H350	GHS08 Dgr	H350’
‘650-060-00-2	Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with supercritical CO2	289-699-3	89997-63-7	Acute Tox. 4 Acute Tox. 4 STOT SE 1 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H332 H302 H370 (nervous system) H373 (respiratory tract, inhalation) H317 H400 H410	GHS07 GHS08 Dgr	H332 H302 H370 (nervous system) H373 (respiratory tract, inhalation) H317 H410		inhalation: ATE = 2,6 mg/L (dusts or mists) oral: ATE = 730 mg/kg bw M = 1 000 M = 100’
‘650-059-00-7	Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with hydrocarbon solvents	289-699-3	89997-63-7	Acute Tox. 4 Acute Tox. 4 STOT SE 1 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H332 H302 H370 (nervous system) H373 (respiratory tract, inhalation) H317 H400 H410	GHS07 GHS08 Dgr	H332 H302 H370 (nervous system) H373 (respiratory tract, inhalation) H317 H410		inhalation: ATE = 2,6 mg/L (dusts or mists) oral: ATE = 730 mg/kg bw M = 1 000 M = 100’
‘607-777-00-0	barium bis[2-chloro-5-[(2-hydroxy-1-naphthyl)azo]toluene-4-sulphonate]; C.I. Pigment Red 53:1	225-935-3	5160-02-1	Carc. 2	H351	GHS08 Wng	H351’
‘608-070-00-X	2-bromo-2-(bromomethyl)pentanedinitrile; [DBDCB]	252-681-0	35691-65-7	Acute Tox. 2 Acute Tox. 4 STOT RE 2 Eye Dam. 1 Skin Sens. 1A Aquatic Chronic 2	H330 H302 H373 (thyroid, central nervous system) H318 H317 H411	GHS06 GHS08 GHS05 GHS09 Dgr	H330 H302 H373 (thyroid, central nervous system) H318 H317 H411		inhalation: ATE = 0,27 mg/L (dusts or mists) oral: ATE = 500 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,001 %’
‘607-779-00-1	9-octadecenoic acid (Z)-, sulfonated, potassium salts [1]; Reaction products of fatty acids, C18 (unsaturated) alkyl with sulfur trioxide, potassium salts [2]; 9(or 10)-sulphooctadecanoic acid, potassium salt [3]	271-843-1 [1]; - [2]; 267-966-5 [3]	68609-93-8 [1]; - [2]; 67968-63-2 [3]	Repr. 1B	H360D	GHS08 Dgr	H360D’
‘613-352-00-0	bixlozone (ISO); 2-(2,4-dichlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one	—	81777-95-9	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 1 M = 10’
‘603-248-00-3	2,3-epoxypropyl isopropyl ether	223-672-9	4016-14-2	Repr. 1B	H360F	GHS08 Dgr	H360F’
‘607-778-00-6	tetrahydrofurfuryl methacrylate	219-529-5	2455-24-5	Repr. 1B Skin Sens. 1A	H360Df H317	GHS08 GHS07 Dgr	H360Df H317’
‘015-209-00-2	trimethyl phosphate	208-144-8	512-56-1	Carc. 1B Muta. 1B Repr. 1B Acute Tox. 4 STOT RE 2	H350 H340 H360FD H302 H373 (nervous system)	GHS08 GHS07 Dgr	H350 H340 H360FD H302 H373 (nervous system)		oral: ATE = 1 300 mg/kg bw’
‘602-111-00-5	fluoroethylene	200-832-6	75-02-5	Carc. 1A Muta. 2	H350 H341	GHS08 Dgr	H350 H341			D’
‘602-112-00-0	2-bromo-3,3,3-trifluoroprop-1-ene	—	1514-82-5	Repr. 1B STOT SE 3 STOT SE 3	H360FD H335 H336	GHS08 GHS07 Dgr	H360FD H335 H336’
‘613-353-00-6	2-methyl-2H-isothiazol-3-one hydrochloride; 2-methyl-2,3-dihydro-1,2-thiazol-3-one hydrochloride	247-499-3	26172-54-3	Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Acute Aquatic 1 Acute Chronic 1	H330 H311 H301 H314 H318 H317 H400 H410	GHS06 GHS05 GHS09 Dgr	H330 H311 H301 H314 H317 H410	EUH071	inhalation: ATE = 0,15 mg/L (dusts or mists) dermal: ATE = 320 mg/kg bw oral: ATE = 180 mg/kg bw Skin. Sens 1A; H317: C ≥ 0,0015 % M = 10 M = 1’
‘603-249-00-9	2,3-epoxypropyl o-tolyl ether	218-645-3	2210-79-9	Skin Irrit. 2 Skin Sens. 1A Muta. 2 Aquatic Chronic 2	H315 H317 H341 H411	GHS07 GHS08 GHS09 Wng	H315 H317 H341 H411			C’
‘607-780-00-7	methyl oct-2-ynoate	203-836-6	111-12-6	Skin Sens. 1A	H317	GHS07 Wng	H317’
‘612-301-00-X	dinotefuran (ISO); (RS)-1-methyl-2-nitro-3-(tetrahydro-3-furylmethyl)guanidine	-	165252-70-0	Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1	H302 H400 H410	GHS07 GHS09 Wng	H302 H410		oral: ATE = 2 000 mg/kg bw M = 10 M = 10’

(2) the entries corresponding to index numbers 015-012-00-1, 601-027-00-6, 602-025-00-8, 607-231-00-1, 613-044-00-6, 613-045-00-1, 615-008-00-5, 616-145-00-3, 616-211-00-1, 616-212-00-7 are replaced by the following entries respectively:

Index No	Chemical Name	EC No	CAS No	Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)	Specific Conc. Limits, M-factors and ATEs	Notes
‘601-027-00-6	2-phenylpropene; α-methylstyrene	202-705-0	98-83-9	Flam. Liq. 3 Carc. 2 STOT SE 3 Eye Irrit. 2 Skin Sens. 1B Aquatic Chronic 2	H226 H351 H335 H319 H317 H411	GHS02 GHS08 GHS07 GHS09 Wng	H226 H351 H335 H319 H317 H411		STOT SE 3; H335: C ≥ 25 %	D’
‘616-145-00-3	pethoxamid (ISO); 2-chloro-N-(2-ethoxyethyl)-N-(2-methyl-1-phenylprop-1-enyl)acetamide	-	106700-29-2	Acute Tox. 4 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H302 H317 H400 H410	GHS07 GHS09 Wng	H302 H317 H410		oral: ATE = 980 mg/kg bw M = 100 M = 10’
‘015-012-00-1	tetraphosphorus trisulphide; phosphorus sesquisulphid	215-245-0	1314-85-8	Flam. Sol. 1 Self-heat. 1 Acute Tox. 4*	H228 H251 H302	GHS02 GHS07 Dgr	H228 H251 H302			T’
‘602-025-00-8	1,1-dichloroethylene; vinylidene chloride	200-864-0	75-35-4	Flam. Liq. 1 Carc. 1B Muta. 2 Acute Tox. 1 Acute Tox. 3 STOT RE 1 Aquatic Chronic 3	H224 H350 H341 H330 H301 H372 (respiratory tract, kidney, liver) H412	GHS02 GHS08 GHS06 Dgr	H224 H350 H341 H330 H301 H372 (respiratory tract, kidney, liver) H412		inhalation: ATE = 0,5 mg/L (vapours) oral: ATE = 300 mg/kg bw	D’
‘615-008-00-5	3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate; isophorone di-isocyanate	223-861-6	4098-71-9	Acute Tox. 1 Skin Corr. 1 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 2	H330 H314 H334 H317 H411	GHS06 GHS05 GHS08 GHS09 Dgr	H330 H314 H318 H334 H317 H411	EUH071	inhalation: ATE = 0,03 mg/L (dusts or mists) Resp. Sens. 1; H334: C ≥ 0,5 % Skin Sens. 1A; H317: C ≥ 0,001 %	2’
‘613-045-00-1	folpet (ISO); N-(trichloromethylthio)phthalimide	205-088-6	133-07-3	Carc. 2 Acute Tox. 2 STOT RE 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H351 H330 H372 (respiratory tract) H318 H317 H400 H410	GHS08 GHS06 GHS05 GHS09 Dgr	H351 H330 H372 (respiratory tract) H318 H317 H410	EUH066	inhalation: ATE = 0,30 mg/L (dusts or mists) STOT RE 1: C ≥ 5 % STOT RE 2: 0,5 % ≤ C < 5 % Skin Sens. 1A; H317: C ≥ 0,001 % M = 10 M = 10’
‘613-044-00-6	captan (ISO); 1,2,3,6-tetrahydro-N-(trichloromethylthio)phthalimide	205-087-0	133-06-2	Carc. 2 Repr. 2 Acute Tox. 2 STOT RE 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H351 H361f H330 H372 H318 H317 H400 H410	GHS08 GHS06 GHS05 GHS09 Dgr	H351 H361f H330 H372 H318 H317 H410		inhalation: ATE = 0,22 mg/L (dusts or mists) Skin Sens. 1A; H317: C≥ 0,001 % M = 10 M = 10’
‘607-231-00-1	clopyralid (ISO); 3,6-dichloropyridine-2-carboxylic acid	216-935-4	1702-17-6	Eye Dam. 1 Aquatic Chronic 1	H318 H410	GHS05 GHS09 Dgr	H318 H410	EUH066	M = 10’
‘616-211-00-1	proquinazid (ISO); 6-iodo-2-propoxy-3-propylquinazolin-4(3H)-one	—	189278-12-4	Carc. 2 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H351 H372 (thyroid, liver) H400 H410	GHS08 GHS09 Dgr	H351 H372 (thyroid, liver) H410		M = 1 M = 10’
‘616-212-00-7	3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate	259-627-5	55406-53-6	Acute Tox. 2 Acute Tox. 4 STOT RE 1 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H330 H302 H372 (larynx) H318 H317 H400 H410	GHS06 GHS08 GHS05 GHS09 Dgr	H330 H302 H372 (larynx) H318 H317 H410		inhalation: ATE = 0,17 mg/L (dusts or mists) M = 10 M = 10’

If you need any assistance or have any questions, please get in touch with us via service@cirs-group.com.

Further Information

Official Journal of the European Union